Track Praxis Precision Medicines, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Praxis Precision Medicines, Inc. PRAX · Stock Open Praxis Precision Medicines, Inc. in new tab

328.13 USD
EPS
-12.82
P/B
7.38
ROE
-44.84
Beta
2.84
Target Price
675.80 USD
Loading chart...
Key Metrics
Earnings dateFeb. 18, 2027
EPS-12.82
Book Value45.15
Price to Book7.38
Debt/Equity0.06
% Insiders0.276%
Estimates
Forward P/E-34.33
Forward EPS-9.70
Target Mean Price675.80

DCF valuation

Model fair value for Praxis Precision Medicines, Inc. (PRAX)
Result
Sign in to run the valuation for PRAX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
20 analysts · consensus Strong buy · mean target 675.80 USD (low 362.00, high 1201.00) · as of 10 Nov 2026
Low 362.00
Mean 675.80
High 1201.00
Price 328.13
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Praxis Precision Medicines, Inc. Logo Praxis Precision Medicines, Inc. Analysis (PRAX)

United States Health Care Official Website Stock

Is Praxis Precision Medicines, Inc. a good investment? Praxis Precision Medicines, Inc. (PRAX) is currently trading at 328.13 USD. Market analysts have a consensus price target of 675.80 USD. This suggests a potential upside from current levels.

Earnings Schedule: Praxis Precision Medicines, Inc. is expected to release its next earnings report on Feb. 18, 2027. The market consensus estimate for Forward EPS is -9.70.

Investor FAQ

Does Praxis Precision Medicines, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Praxis Precision Medicines, Inc.?

Praxis Precision Medicines, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 18, 2027. The company currently has a trailing EPS of -12.82.

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Exchange Ticker
NMS (United States) PRAX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 29, 2023 1:15
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion